Florian Rader

Dr. Florian Rader

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in Circulation
Verified
Journal Article
Open access
PDF file
HJHongwei Ji
Hongwei Ji
TNTeemu Niiranen
Teemu Niiranen
FRFlorian Rader
Florian Rader
MHMir Henglin
Mir Henglin
AKAndy Kim
Andy Kim
SCSusan Cheng
Susan Cheng

2 January 2024 in JACC: Heart Failure
Verified
Journal Article
Open access
FRFlorian Rader
Florian Rader
AOArtur Oreziak
Artur Oreziak
LCLubna Choudhury
Lubna Choudhury
SSSara Saberi
Sara Saberi
DFDavid Fermin
David Fermin
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy are needed. The authors sought to evaluate interim results from the EXPLORER-Long Term Extension (LTE) cohort of MAVA-LTE (A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed EXPLORER-HCM; NCT03723655). After mavacamten or placebo withdrawal at the end of the parent EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545), patients could enroll in MAVA-LTE. Patients received mavacamten 5 mg once daily; adjustments were made based on site-read echocardiograms. Between April 9, 2019, and March 5, 2021, 231 of 244 eligible patients (94.7%) enrolled in MAVA-LTE (mean age: 60 years; 39% female). At data cutoff (August 31, 2021) 217 (93.9%) remained on treatment (median time in study: 62.3 weeks; range: 0.3-123.9 weeks). At 48 weeks, patients showed improvements in left ventricular outflow tract (LVOT) gradients (mean change ± SD from baseline: resting: -35.6 ± 32.6 mm Hg; Valsalva: -45.3 ± 35.9 mm Hg), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (median: -480 ng/L; Q1-Q3: -1,104 to -179 ng/L), and NYHA functional class (67.5% improved by ≥1 class). LVOT gradients and NT-proBNP reductions were sustained through 84 weeks in patients who reached this timepoint. Over 315 patient-years of exposure, 8 patients experienced an adverse event of cardiac failure, and 21 patients had an adverse event of atrial fibrillation, including 11 with no prior history of atrial fibrillation. Twelve patients (5.2%) developed transient reductions in site-read echocardiogram left ventricular ejection fraction of <50%, resulting in temporary treatment interruption; all recovered. Ten patients discontinued treatment due to treatment-emergent adverse events. Mavacamten treatment showed clinically important and durable improvements in LVOT gradients, NT-proBNP levels, and NYHA functional class, consistent with EXPLORER-HCM. Mavacamten treatment was well tolerated over a median 62-week follow-up.

1 April 2015 in The American Journal of Medicine
Verified
Journal Article
Closed access
FRFlorian Rader
Florian Rader
ESEsha Sachdev
Esha Sachdev
RAReza Arsanjani
Reza Arsanjani
RSRobert J. Siegel
Robert J. Siegel

1 January 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ANAdam D. Niku
Adam D. Niku
TSTakahiro Shiota
Takahiro Shiota
RSRobert J. Siegel
Robert J. Siegel
FRFlorian Rader
Florian Rader

15 March 2024 in Journal of Cardiac Failure
Verified
Journal Article
Open access
AMAhmad Masri
Ahmad Masri
MSMark V. Sherrid
Mark V. Sherrid
TATheodore P. Abraham
Theodore P. Abraham
LCLubna Choudhury
Lubna Choudhury
PGPablo Garcia-Pavia
Pablo Garcia-Pavia
MMMartin S. Maron
Martin S. Maron
This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤30 mmHg, left ventricular ejection fraction [LVEF] ≥60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] >300 pg/mL) received aficamten 5-20 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. 41 patients were enrolled (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP (56%; P < 0.001) and high-sensitivity cardiac troponin I (22%; P < 0.005). Modest reductions in LVEF (mean ± SD) of -5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF <50% (range: 41-48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study. Aficamten administration for symptomatic nHCM was generally safe and associated with improvements in heart failure symptoms and cardiac biomarkers. ClinicalTrials.gov Identifier: NCT04219826 LAY SUMMARY: Non-obstructive hypertrophic cardiomyopathy (nHCM) is a disease in which the heart muscle becomes abnormally thickened. There are no proven medical therapies. Aficamten is a new cardiac myosin inhibitor designed to target the underlying cause of HCM. REDWOOD-HCM Cohort 4 was the first study exploring the efficacy and safety of aficamten in people with symptoms from nHCM. Most patients reported improved health and functional status. There was also significant decrease in blood levels of biomarkers indicating excessive pressure within the heart and damage to heart muscle cells. These results support a larger placebo-controlled study of aficamten for people with nHCM (ACACIA-HCM).

1 March 2015 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
VPVishal Parikh
Vishal Parikh
CKCandice Kim
Candice Kim
RSRobert J. Siegel
Robert J. Siegel
RAReza Arsanjani
Reza Arsanjani
FRFlorian Rader
Florian Rader